Unravelling survival pathways: the road to next-generation chronic myeloid leukaemia drugs?
Department of Hematology-Medical Oncology, H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare, Belgium. Electronic address: ddeeren@hhr.be.
Dries
D
Deeren
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology*; D049109:Cell Proliferation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D048670:MAP Kinase Kinase 4 / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D011743:Pyrimidines / Q000494:pharmacology*; D051153:Wnt Proteins / Q000378:metabolism*; D000071818:Wnt-5a Protein; D051185:gamma Catenin / Q000378:metabolism*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011518:Proto-Oncogene Proteins; D011743:Pyrimidines; C085389:WNT5A protein, human; D051153:Wnt Proteins; D000071818:Wnt-5a Protein; D051185:gamma Catenin; D000068877:Imatinib Mesylate; D048670:MAP Kinase Kinase 4
Azacitidine; BCR-ABL positive; Chronic; Imatinib; Leukemia; Myelogenous; Wnt signaling pathway; β-Catenin